ReviewEuropean journal of obstetrics & gynecology and reproductive biology: X2026
Prediction models for endometriosis-associated ovarian malignancy: A systematic review and meta-analysis.
Review in European journal of obstetrics & gynecology and reproductive biology: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endometriosis is benign, but it is associated with an increased risk of clear-cell and endometrioid ovarian carcinoma. Several multivariable prediction models have been developed to identify malignant transformation or differentiate endometriosis-associated ovarian cancer (EAOC) from benign ovarian endometrioma. It remains unclear whether these models are sufficiently validated and reported for clinical use. Methods: We searched PubMed, Embase, Web of Science, the Cochrane Library, CINAHL, Scopus, CNKI, Wanfang, VIP, and SinoMed from inception to 24 May 2025. We included reports that developed or evaluated a multivariable model for endometriosis-associated ovarian malignancy. Two reviewers independently selected studies, extracted data with the CHARMS framework, and assessed risk of bias with PROBAST. Studies were grouped by clinical purpose and by evaluation stage. AUCs were pooled on the logit scale with restricted maximum-likelihood random-effects models only within clinically comparable groups. Adjusted ORs were pooled on the log scale when predictor definitions and reference categories were compatible. Results: Eighteen reports describing heterogeneous model-development or model-evaluation studies were included. Logistic regression was the predominant modeling approach, whereas several studies evaluated nomograms, rule-based models, and machine-learning algorithms. In the exploratory stratified analyses, the pooled AUC was 0.907 (95% CI 0.874-0.932) for model-development or apparent-performance datasets and 0.915 (95% CI 0.880-0.941) for internal validation datasets. The two independent external or temporal evaluations were not pooled. Threshold-defined maximum tumor diameter (OR 1.85, 95% CI 1.64-2.08) and intratumoral blood flow (OR 3.90, 95% CI 1.73-8.80) showed positive pooled associations, whereas dysmenorrhea was not statistically significant. Calibration was inconsistently reported, and all included studies had an overall high risk of bias. Six reports presented calibration plots, two reported a Brier score, and seven presented decision-curve analysis; none reported a calibration intercept or slope. Conclusion: Current models often report high discrimination, but the supporting evidence is limited by high risk of bias, inconsistent calibration reporting, few independent validations, and geographic concentration. Routine use is premature. The most promising models should first undergo prospective external validation, calibration assessment, and evaluation of clinical net benefit in diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.